TSX Exchange Symbol: RVX
CALGARY, Oct. 1, 2014 /CNW/ - Resverlogix Corp. (TSX:RVX) will be
hosting a corporate update conference call and webcast on Monday,
October 6, 2014 at 11 am MDT / 1 pm ET.
Details for the conference call and webcast are as follows:
Link to webcast: http://services.choruscall.ca/links/resverlogix141006.html
Dial in numbers:
Canada & USA Toll Free Dial In: 1-800-319-4610
Outside of Canada & USA call: +1-604-638-5340
About Resverlogix
Resverlogix Corp. (TSX: RVX) is a clinical stage cardiovascular company
developing compounds involving a therapeutic increase in ApoA-I.
RVX-208 is a first-in-class small molecule for the treatment of
atherosclerosis and other chronic diseases such as Diabetes Mellitus
and Alzheimer's disease. RVX-208 is the first BET bromodomain inhibitor
in clinical trials. Resverlogix's common shares trade on the Toronto
Stock Exchange (TSX: RVX). For further information please visit www.resverlogix.com. We can be followed on our blog at http://www.resverlogix.com/blog.
| Company Contacts:
|
|
|
|
|
|
|
|
|
| Donald J. McCaffrey |
|
| Sarah Zapotichny |
|
President and CEO
|
|
|
Director, Investor Relations
|
|
Resverlogix Corp.
|
|
|
Resverlogix Corp.
|
|
Phone: 403-254-9252
|
|
|
Phone: 403-254-9252
|
|
Email: don@resverlogix.com
|
|
|
Email: sarah@resverlogix.com |
|
|
|
|
|
SOURCE Resverlogix Corp.
